Defence Therapeutics Inc. (DTCFF)
USD 0.62
(3.69%)
USD 0.62
(3.69%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 12.65 Million CAD | 95.29% |
| 2023 | 6.48 Million CAD | -11.47% |
| 2022 | 7.32 Million CAD | 156.02% |
| 2021 | 2.85 Million CAD | 324.74% |
| 2020 | 673.18 Thousand CAD | 1504.88% |
| 2019 | 41.94 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.11 Million CAD | 22.51% |
| 2024 Q2 | 8.3 Million CAD | 292.57% |
| 2024 Q3 | 1.21 Million CAD | -85.42% |
| 2024 Q4 | 1.18 Million CAD | -7.02% |
| 2023 Q4 | 1.72 Million CAD | 38.98% |
| 2023 Q3 | 1.24 Million CAD | -35.08% |
| 2023 Q2 | 1.91 Million CAD | 15.01% |
| 2023 FY | 6.53 Million CAD | -10.77% |
| 2023 Q1 | 1.66 Million CAD | -23.41% |
| 2022 Q1 | 1.52 Million CAD | -9.19% |
| 2022 Q3 | 1.67 Million CAD | -13.59% |
| 2022 Q4 | 2.17 Million CAD | 29.49% |
| 2022 FY | 7.32 Million CAD | 156.02% |
| 2022 Q2 | 1.94 Million CAD | 26.87% |
| 2021 Q3 | 690.74 Thousand CAD | 56.19% |
| 2021 FY | 2.85 Million CAD | 324.74% |
| 2021 Q1 | 41.5 Thousand CAD | -91.2% |
| 2021 Q4 | 1.68 Million CAD | 143.9% |
| 2021 Q2 | 442.25 Thousand CAD | 965.55% |
| 2020 Q3 | 192.27 Thousand CAD | 6601.64% |
| 2020 Q1 | 6536.00 CAD | 0.0% |
| 2020 Q2 | 2869.00 CAD | -56.1% |
| 2020 FY | 673.18 Thousand CAD | 1504.88% |
| 2020 Q4 | 471.5 Thousand CAD | 145.23% |
| 2019 FY | 41.94 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bioxytran, Inc. | 3.82 Million USD | -231.291% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 85.417% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -4735.516% |
| SQZ Biotechnologies Company | 85.61 Million USD | 85.218% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -333.977% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 57.176% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 66.03% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -742.653% |
| Marizyme, Inc. | 19.23 Million USD | 34.221% |
| Genus plc | 147.7 Million USD | 91.431% |
| Pharming Group N.V. | 225.49 Million USD | 94.387% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -517.746% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -843.375% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -51.766% |
| ContraFect Corporation | 56.88 Million USD | 77.754% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -755.843% |
| IMV Inc. | 37.7 Million USD | 66.438% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -353.555% |
| ONE Bio Corp. | 6.44 Million USD | -96.4% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 85.275% |
| Mesoblast Limited | 5.9 Million USD | -114.432% |
| MultiCell Technologies, Inc. | 567.42 USD | -2230311.688% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 48.793% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.467% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -3148.693% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -381.663% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -157.341% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1172.986% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -619.211% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -88.386% |
| Skye Bioscience, Inc. | 13.54 Million USD | 6.582% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -578.825% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -44.156% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 50723.208% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -187.066% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -151.005% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 20.952% |
| Accustem Sciences Inc. | 3.74 Million USD | -237.811% |
| EV Biologics, Inc. | 531.96 Thousand USD | -2279.08% |
| Q BioMed Inc. | 3.43 Million USD | -268.262% |
| GB Sciences, Inc. | 1.42 Million USD | -790.934% |
| Alpha Cognition Inc. | 9.7 Million USD | -30.397% |
| CSL Limited | 3.44 Billion USD | 99.633% |
| Agentix Corp. | 1.37 Million USD | -822.599% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 87.259% |
| Enzolytics Inc. | 2.17 Million USD | -480.673% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 12.71 Million USD | 0.442% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -246.667% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -589.654% |
| argenx SE | 1.53 Billion USD | 99.175% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 77.967% |
| HST Global, Inc. | 140.9 Thousand USD | -8881.67% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1112.242% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1025.05% |
| Halberd Corporation | 74.84 Thousand USD | -16810.026% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -426.243% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -271.685% |
| Zenith Capital Corp. | 8.94 Million USD | -41.516% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -701.327% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -415.445% |
| AVAX Technologies, Inc. | 7.31 Million USD | -73.124% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -7279.089% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -558.845% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -72546.817% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -413.053% |
| Helix BioMedix, Inc. | 1.97 Million USD | -541.764% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -16.461% |
| Kadimastem Ltd | 2.41 Million USD | -425.113% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 44.914% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -6873.47% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -847.694% |
| LadRx Corporation | 3.81 Million USD | -232.017% |
| Cell Source, Inc. | 4.32 Million USD | -192.596% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -2946.075% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1270.402% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1270.402% |
| Affymax, Inc. | 39.38 Million USD | 67.867% |
| Mobile Lads Corp. | 554.54 Thousand USD | -2182.192% |
| Itoco Inc. | 919.14 Thousand USD | -1276.913% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -198.598% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1030.992% |
| International Stem Cell Corporation | 5.27 Million USD | -140.102% |
| CytoDyn Inc. | 18.05 Million USD | 29.916% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -50183.293% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -5650.598% |
| Qrons Inc. | 643.67 Thousand USD | -1866.173% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -791.384% |
| SYBLEU INC | 160.87 Thousand USD | -7766.805% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -467.556% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1805.994% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -596.783% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -23941.264% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -62112.073% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 65.103% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -682.188% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1619.924% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -306.808% |
| Neutra Corp. | 243.82 Thousand USD | -5090.612% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 27.503% |
| PureTech Health plc | 144.59 Million USD | 91.248% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 38.234% |
| IXICO plc | 4.7 Million USD | -168.872% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -43.865% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 89.252% |
| CSL Limited | 3.89 Billion USD | 99.675% |
| Cellectis S.A. | 97.32 Million USD | 86.996% |